* EBIT 10% below ABGSC, 12% below consensus * 32% organic growth (vs ABGSC 16%), 6% order backlog gr...
* Aims to grow DTC by ~30% CAGR next three years * We lower our '26e-'27e EBITA by 3-2% on cost ramp...
Redeye provides its first take on Oncopeptides' Q3 report 2025.
Redeye notes a somewhat mixed Q3, with a sales miss due to lower distributor sales (Thermo) and a we...
Redeye comments on G5’s Q3-results which were somewhat softer than expected, mainly due to higher-th...
Redeye provides an update on Scandinavian ChemoTech following the Q3 2025 report.
NoHo Partners' Q3 2025 was challenging, mainly due to Norway, where the market keeps declining and t...
Cargo tonnes grew by 8% and the number of passengers increased by 1.
* Major beat on EBIT, but lower sales * Estimates up on adj.
* Q3 beat our expectations handily, EBITA 29% above * Raise '26e-'27e EBITA 15-14% on higher margin ...
Redeye comments on the news from VGR regarding its future healthcare information environment.
* Q3e Paper EBIT of ~PLN 5m * Challenging markets * Fair value range of SEK 17-60 Q3e Paper EBIT of ...
Thunderful did not release any major titles during the third quarter.
Absolent’s Q3 report shows a similar pattern as H1’25, but with some improvements and bright spots.
Enea provided updated financial goals of an average CAGR of 10% over the next three-year period and ...
* Sales -9% & EBIT adj. SEK 7m below vs. ABGSCe * EBIT impacted by SEK +6 m one-off gain from Q3’24 ...
Redeye provides an initial comment on Serstech’s Q3 2025 report.
Redeye provides an initial comment on Scandinavian ChemoTech’s Q3 2025 report.
* Net sales SEK 174m, -3% vs ABGSCe * EBITA SEK 24m, -18% vs ABGSCe * Cole & Son platform to be upgr...
Aspo’s Q3 results were in the end neutral; both ESL and Telko can improve more next year, when they ...
